Drug Profile
Research programme: blood clotting proteins
Alternative Names: Factor IX - Pharming/American Red Cross; Factor VIII - Pharming/American Red Cross; Fibrinogen - Pharming/American Red CrossLatest Information Update: 01 Feb 2005
Price :
$50
*
At a glance
- Originator American Red Cross; Pharming Healthcare
- Developer American Red Cross
- Class
- Mechanism of Action Blood coagulation factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Blood coagulation disorders
Most Recent Events
- 01 Feb 2005 No development reported - Clinical-Phase-Unknown for Coagulation disorders in USA (unspecified route)
- 17 Aug 1999 Investigation in Coagulation disorders in USA (Unknown route)